Amsbio has launched a new range of authenticated cell lines covering a wide range of tumours, tissues, and species. With this addition of greater than 1000 independently verified human and animal cell lines, versatile primary and stem cells, the expanded range of top quality, cell lines from Amsbio are second to none.

The company is committed to providing cells that retain their original genetic composition and phenotypic characteristics, ensuring greater reliability and accuracy can be achieved in experimental results. Detailed documentation of every cell passage underscores the company’s dedication to traceability and reproducibility in research. As a result, researchers can be confident that their cell cultures are completely healthy and ready for outstanding scientific work.

Each cell line, supplied by Amsbio, undergoes a rigorous, multi-step authentication process, in addition to comprehensive sterility and mycoplasma testing, to ensure the highest level of reliability for your research.

Used in the study of multiple biological processes including gene activation, protein-protein interactions, cell signalling and differentiation – cell lines are an invaluable tool. Providing a more physiologically relevant option than cell-free assays, cell lines are applicable in a wide range of research areas.

For further information on independently verified cell lines please visit https://www.amsbio.com/products/cells-cell-culture/cell-lines or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected].

Amsbio, part of the Europa Biosite group, is a leading life sciences company supporting drug discovery, translational research, and cell and gene therapy across Europe, North America, and wider international markets. With in depth expertise in advanced cell culture, 3D cell models, and cryopreservation, Amsbio is well placed to help researchers progress from early discovery through to clinical and GMP-ready applications. The company’s portfolio of innovative products and services supports multiple stages of the research pipeline, spanning target discovery, assay development, and disease modelling, through to stem cell and organoid-based research. Key solutions include the integrated stem call platform combining StemFit™ media, iMatrix™ recombinant laminins, and CELLBANKER™ cryopreservation technology, alongside extracellular matrix technologies, biospecimens, glycobiology tools, kits and assays, and a wide range of custom services including viral delivery. Drawing on extensive GMP expertise and a comprehensive human and animal biorepository, Amsbio is internationally recognized for delivering high-quality, application-ready products and services. Amsbio has a consistent record of close scientific collaboration with partners in academic, biotech, and pharmaceutical markets to translate innovation from bench to bedside.